This article describes the results of a 18‐week double‐blind clinical trial, assessing the effects of imeglimin on insulin secretion and sensitivity using an oral glucose tolerance test in Caucasian Type 2 Diabetic patients. This evidence concerns the gene INS and type 2 diabetes mellitus.